Compared with standard glutathione (500 mg), LipoMicel at a lower dose (300 mg) increased iAUC and C max by ~2.49-fold and ~2.43-fold, respectively, and when dose-normalized (to a 300 mg equivalent), incremental systemic exposure and peak levels were up to ~4-fold higher, supporting greater absorption per unit dose. The findings indicate LipoMicel is a promising delivery method for oral glutathione, though the researchers added larger, long-term studies are still needed
Healthcare providers should be aware of the possible dangers associated with these drugs, and careful monitoring is recommended for patients with renal or hepatic impairment, as well as for the elderly
These side effects can occur due to a rapid escalation of dosage
[1] Most are administered via subcutaneous injection, with dosing frequencies ranging from twice daily to once weekly, depending on the specific formulation
In preclinical models, these mechanisms translate into broad potential applications, including wound healing, muscle and tendon repair, gastrointestinal ulcer protection, and recovery from NSAID-induced damage
Treatments are not substitutes for lifestyle modification
